Crystal Pharmatech Co., Ltd.

Anacor Pharmaceuticals, Inc.

Crystal Pharmaceutical (suzhou) Co., Ltd.

Nan Xia

Yanfeng Zhang

Minhua Chen

Xiaoyu Zhang

Chaohui Yang

Xiaojuan Diao

Fei Lu

Chunxiang Huang

Qiyue Liu

Lie Chen

The present invention relates to four crystal forms of crisaborole in free form and the preparation method thereof. The present invention also relates to the pharmaceutical composition containing the crystal forms and the use thereof.

Crystal forms of crisaborole in free form and preparation method and use thereof

The present disclosure relates to novel crystalline forms of VX-787, processes for preparation thereof and use thereof. VX-787 is a viral-protein inhibitor drug. The present disclosure provides crystalline form CS1, crystalline form CS2, crystalline form CS3, and crystalline form CS4 of compound (I) hydrochloride. The present disclosure also provides crystalline form CS3 and crystalline form CS9 of compound (I).free form. 

Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereof

The present disclosure relates to novel crystalline forms of JAK inhibitors and the preparation method thereof. The novel crystalline forms in the present disclosure can be used for the treatment of autoimmune diseases, particularly for the treatment of rheumatoid arthritis. The novel crystalline forms in the present disclosure have good stability and remarkable purification effect in process, moreover, its solubility and hygroscopicity meet the requirements for medical use. The preparation method of novel crystalline forms is simple, low cost, and has an important value for future optimization and development of the drug. 

Crystal form of JAK inhibitor and preparation method thereof

The present disclosure relates to novel co-crystals of a CDK inhibitor and an MEK inhibitor and the preparation methods thereof. Specifically, the present disclosure provides hydrates or anhydrates which are named as Form I, Form II and Form III. The novel co-crystals provided in the present disclosure have good stability, low hygroscopicity and high solubility, and have an important value for further optimization and development of the drug. 

Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof

The present disclosure relates to crystalline Form &#x3b1; of a compound of formula (I) used for preparing a blood-cancer drug and preparation method thereof. The crystalline Form &#x3b1; in the present disclosure has better stability, and its solubility and hygroscopicity meet the requirements of medical use. Form &#x3b1; has simple preparation method and low manufacturing cost, and provides great value to future optimization and development of this drug. 

Growing community of inventors

Jiangsu, China

Nan Xia